Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus

  • Type 2 diabetes is characterized by impaired insulin sensitivity and disturbances in β-cell function. While glimepiride stimulates β-cell secretion and leads to a reduction of blood glucose levels, pioglitazone activates peroxisome proliferator-activated receptor-γ and improves insulin resistance. Combining these two modes of action has been shown to improve glucose and lipid metabolism, and to improve the overall cardiovascular risk in patients with Type 2 diabetes. The combination of glimepiride and pioglitazone is generally well tolerated and a fixed combination may lead to an improved compliance in patients. The purpose of this review is to evaluate the clinical data that has been published on this combination, appearing to represent a convenient way to obtain therapeutic targets in patients with Type 2 diabetes mellitus.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Availability
Document Type:Article
Author:Thomas Forst, Andreas Pfützner
Parent Title (English):Expert review of endocrinology & metabolism
First Page:303
Last Page:312
Pubmed Id:
Publisher:Future Drugs Ltd
Publication year:2007
Tag:glimepiride; pioglitazone; sulfonylurea; thiazolidinediones; type 2 diabetes mellitus
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Entry in this database:2019/02/22